SG Americas Securities LLC Invests $40,000 in Rallybio Co. (NASDAQ:RLYB)

SG Americas Securities LLC purchased a new stake in shares of Rallybio Co. (NASDAQ:RLYB) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 16,813 shares of the company’s stock, valued at approximately $40,000.

Other institutional investors also recently bought and sold shares of the company. UBS Group AG increased its position in Rallybio by 44.2% during the first quarter. UBS Group AG now owns 7,056 shares of the company’s stock valued at $40,000 after acquiring an additional 2,164 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Rallybio by 17.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 15,289 shares of the company’s stock worth $107,000 after purchasing an additional 2,224 shares during the period. California State Teachers Retirement System grew its holdings in Rallybio by 45.4% during the 2nd quarter. California State Teachers Retirement System now owns 10,170 shares of the company’s stock valued at $58,000 after purchasing an additional 3,175 shares during the last quarter. Royal Bank of Canada lifted its stake in Rallybio by 312.9% in the second quarter. Royal Bank of Canada now owns 4,348 shares of the company’s stock worth $25,000 after purchasing an additional 3,295 shares during the last quarter. Finally, State Street Corp boosted its position in shares of Rallybio by 1.5% during the third quarter. State Street Corp now owns 252,592 shares of the company’s stock valued at $3,655,000 after buying an additional 3,642 shares during the period. 90.34% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently weighed in on RLYB. HC Wainwright reduced their price target on Rallybio from $12.00 to $9.00 and set a “buy” rating on the stock in a report on Wednesday, March 13th. JMP Securities reiterated a “market outperform” rating and issued a $8.00 target price on shares of Rallybio in a research note on Thursday. Jefferies Financial Group lowered shares of Rallybio from a “buy” rating to a “hold” rating in a research note on Wednesday, February 7th. Finally, Wedbush reduced their price target on shares of Rallybio from $13.00 to $11.00 and set an “outperform” rating on the stock in a research note on Thursday, April 11th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, Rallybio has an average rating of “Moderate Buy” and a consensus price target of $12.20.

Rallybio Trading Up 5.4 %

Shares of Rallybio stock opened at $1.76 on Monday. Rallybio Co. has a 12 month low of $1.23 and a 12 month high of $9.14. The stock’s fifty day moving average price is $1.81 and its 200-day moving average price is $2.32. The firm has a market cap of $66.55 million, a P/E ratio of -0.96 and a beta of -1.64.

Rallybio (NASDAQ:RLYB) last posted its earnings results on Tuesday, March 12th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.06). Analysts forecast that Rallybio Co. will post -1.52 earnings per share for the current year.

About Rallybio

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.